Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The legal team said the jury's decision could make medics think twice before allowing the injured to return to the field.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.
Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’
After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.
FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years
Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial
Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children
1.
The majority of cancer medications that receive expedited approval end up failing confirmatory trials.
2.
Year in Review: Non-Small Cell Lung Cancer
3.
EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.
4.
Independent Risk Factors for "Deaths of Despair" Found.
5.
In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.
1.
Cardio-Oncology: Managing Heart Failure in Survivors of Cancer
2.
Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained
3.
Unmasking the Hidden Symptoms of Ovarian Cancer
4.
Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
2.
Oropharyngeal Cancer in Relation to HPV Status
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
5.
Navigating the Complexities of Ph Negative ALL - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge